Year-end Sale % OFF 
Abstract
Response: We thank Drs Lidove, Joly, and Touze1 for their interest in our publications with regard to screening for Fabry disease in stroke patients, and for their analysis of currently available epidemiological data.2,–,6 Several issues, however, preclude drawing solid conclusions from their meta-analysis. First, relevant heterogeneity in the study designs exists, especially with regard to the stroke subtype, the stroke etiology, and the demographic data, and even the screening methodology should be taken into account.2,4,5 Second, limiting screening for Fabry disease to cryptogenic stroke patients may result in selection bias because the condition is known to be associated …
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
